Novartis (NVS)
(Delayed Data from NYSE)
$113.86 USD
-0.09 (-0.08%)
Updated Oct 7, 2024 04:00 PM ET
After-Market: $113.88 +0.02 (0.02%) 7:58 PM ET
3-Hold of 5 3
B Value D Growth A Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$113.86 USD
-0.09 (-0.08%)
Updated Oct 7, 2024 04:00 PM ET
After-Market: $113.88 +0.02 (0.02%) 7:58 PM ET
3-Hold of 5 3
B Value D Growth A Momentum B VGM
Zacks News
AbbVie Elezanumab Gets FDA's Fast Track and Orphan Drug Tags
by Zacks Equity Research
AbbVie's (ABBV) elezanumab is presently being evaluated in a phase II study for spinal cord injury.
AC Immune's Candidate Fails in Alzheimer's Disease Study
by Zacks Equity Research
The failure of AC Immune's (ACIU) study on Alzheimer's disease brings this challenging but promising space in focus.
Pfizer Seeks Xalkori's Label Expansion, Gets Priority Review
by Zacks Equity Research
Pfizer's (PFE) sNDA seeking label expansion of lung cancer drug, Xalkori, for a hematologic indication gets priority review from the FDA.
Novartis Announces Data on Tafinlar, Mekinist & Piqray at ESMO
by Zacks Equity Research
Novartis (NVS) announces data from late-stage studies on Tafinlar, Mekinist and Piqray at ESMO 2020.
Rigel Announces Sponsored Mid-Stage Coronavirus Therapy Study
by Zacks Equity Research
Rigel Pharmaceuticals (RIGL) is developing its thrombocytopenia drug, Tavalisse, as a potential treatment for hospitalized COVID-19 patients.
The Zacks Analyst Blog Highlights: Novartis, Zoom Video, Caterpillar, Microsoft, Cisco, Clorox and LHC Group
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Novartis, Zoom Video, Caterpillar, Microsoft, Cisco, Clorox and LHC Group
Corcept's Lead Drug Korlym Aids Growth, Heavy Reliance a Woe
by Zacks Equity Research
Corcept's (CORT) Cushing's syndrome drug Korlym shows a steady progress. Other pipeline candidates are advancing as well. However, heavy dependence on Korlym for growth remains an overhang.
Top Stock Reports for Novartis, Zoom Video & Caterpillar
by Sheraz Mian
Today's Research Daily features new research reports on 12 major stocks, including Novartis (NVS), Zoom Video Communications (ZM) and Caterpillar (CAT).
Novartis' Eye Drug's Safety Label Update Approved by EMA
by Zacks Equity Research
Novartis' (NVS) eye drug Beovu's safety label update receives approval from the Committee for Medicinal Products for Human Use.
Novartis Reports Positive Data on Beovu for DME Indication
by Zacks Equity Research
Novartis (NVS) announces positive data on Beovu from an ongoing late-stage study for the DME indication.
AstraZeneca's Fasenra Meets Endpoint in Rhinosinusitis Study
by Zacks Equity Research
AstraZeneca (AZN) is developing Fasenra under a clinical program as a potential treatment for chronic rhinosinusitis with nasal polyps.
Roche Expands Multiple Sclerosis Portfolio, Starts Studies
by Zacks Equity Research
Roche (RHHBY) expands its MS portfolio by adding pipeline candidate, fenebrutinib. The company also initiates MS studies on fenebrutinib and Ocrevus.
Novartis (NVS) Releases Positive Data on Enerzair Breezhaler
by Zacks Equity Research
Novartis (NVS) posts favorable data on asthma treatment Enerzair Breezhaler at the ERS International Congress 2020.
Ionis to Acquire Remaining Stake in Akcea, Stocks Rally
by Zacks Equity Research
Ionis (IONS) is set to acquire the remaining 24% stake in Akcea Therapeutics (AKCA) in an all-cash deal.
The Zacks Analyst Blog Highlights: Verizon Communications, Novartis, Abbott Laboratories, AT&T, Intuitive Surgical and Northrop Grumman
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Verizon Communications, Novartis, Abbott Laboratories, AT&T, Intuitive Surgical and Northrop Grumman
Bayer Submits Application for Heart Failure Drug in China
by Zacks Equity Research
Bayer (BAYRY) submits a regulatory application seeking approval for vericiguat to treat patients with symptomatic chronic heart failure in China.
Novartis Announces Positive Data on PNH & Cholesterol Drugs
by Zacks Equity Research
Novartis (NVS) announces new positive data on its PNH drug, LNP023, and an investigational cholesterol-lowering treatment, inclisiran.
Pharma Stock Roundup: AZN's Coronavirus Antibody Combo Study, & Other Updates
by Kinjel Shah
AstraZeneca (AZN) begins dosing in phase I study on antibody cocktail therapy to treat COVID-19. Glaxo's (GSK) Blenrep gets approval in Europe.
Top Stock Reports for Verizon, Novartis & Abbott
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Verizon Communications (VZ), Novartis (NVS) and Abbott Laboratories (ABT).
PTC Therapeutics Gets First Milestone Payment for SMA Drug
by Zacks Equity Research
PTC Therapeutics (PTCT) gets first commercial milestone payment from Roche for first commercial sale of Evrysdi in the United States.
Novartis' (NVS) Leukemia Drug Meets Goal in Late-Stage Study
by Zacks Equity Research
Novartis' (NVS) chronic myeloid leukemia candidate meets primary endpoint in a phase III study.
AbbVie Seeks FDA Approval for Rinvoq in Ankylosing Spondylitis
by Zacks Equity Research
AbbVie (ABBV) files an application to the FDA, seeking its nod for a new indication of Rinvoq, which is active ankylosing spondylitis. The drug is already marketed to treat rheumatoid arthritis.
Teva Stock Down on Charges of Illegal Generic Price Fixing
by Zacks Equity Research
Teva (TEVA) has been indicted on charges of conspiring with other generic drugmakers to raise prices for generic drugs.
Novartis' Immunotherapy Fails in Late-Stage Skin Cancer Study
by Zacks Equity Research
Novartis' (NVS) phase III study evaluating the investigational immunotherapy, spartalizumab, in combination with the targeted therapies, Tafinlar and Mekinist, fails to achieve goals.
FDA Nods to Novartis' Kesimpta for Relapsing Forms of MS
by Zacks Equity Research
Novartis (NVS) gains an FDA nod for Kesimpta (ofatumumab) as a subcutaneous injection for relapsing multiple sclerosis. The drug is expected to be available early next month.